In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci

International Journal of Antimicrobial Agents

Volumn 24, Issue 6, 2004, Pages 613-615

  Kim, Jong Bae ^a   Lee, Gyu Sang ^a   Kim, Yun Bong ^d   Kim, Soo Kie ^b,c   Kim, Yong Hae ^d  

^a Department of Nutritional Science and Food Management   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Yonsei University Wonju   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Echinomycin derivatives; VRE; YK2000

Indexed keywords

AGAR; ANTIBIOTIC AGENT; ECHINOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; YK 2000; YK 2005;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG SCREENING; ENTEROCOCCUS; EXPERIMENT; IN VITRO STUDY; INHIBITION KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ECHINOMYCIN; ENTEROCOCCUS FAECIUM; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 8844258137     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.03.018     Document Type: Article

References (12)

1. Heath C.H., Blackmore T.K., Gordon D.L. Emerging resistance in Enterococcus spp. Med. J. Australia. 164:1996;116-120
2. Witte W. Medical consequences of antibiotic use in agriculture. Science. 279:1998;996-997
3. Raad I., Hachem R., Hanna H., Girgawy E., Rolston K., Whimbey E. Treatment of vancomycin-resistant enterococcal infections in the immuno-compromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrobial Agents Chemother. 45:2001;3202-3204
4. Waring M.J. Echinomycin. Pathologie Biologie. 40:1992;1022-1034
5. Waring MJ, Fox KR. Molecular aspects of the intercalation between quinoxaline antibiotic and nucleic acids. In: Neidle S, Waring, MJ, editors. Molecular aspects of anti-cancer drug action. Basingstoke Hampshire, England: Macmillan Publishers Ltd.; 1983. pp. 127-56.
6. Waring M.J., Wakelin L.P.G. Echinomycin: a bifunctional intercalating antibiotic. Nature. 252:1974;653-657
7. Park Y.S., Kim Y.H., Kim S.K., Choi S.J. A new antitumor agent: methyl sulfonium perchlorate of echinomycin. Bioorganic Med Chem Lett. 8:1998;731-734
8. Facklam, R, Sahm, DF, Teixeira LM. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th ed. Washington, DC: American Society for Microbiology, USA; 1999. p. 297-305.
9. Facklam R., Elliott J.A. Identification, classification, and clinical relevance of catalase-negative gram-positive cocci, including streptococci and enterococci. Clin Microbiol Rev. 8:1995;479-495
10. Patel R., Uhl J.R., Kohner P., Hopkins M.K., Cockerill F.R. III Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci. J. Clin. Microbiol. 35:1997;703-707
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria to grow aerobically. 3rd ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Villanova, PA, USA; 2000.
12. Moellering R.C. Jr. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J. Antimicrob. Chemother. 28:1991;1-12